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Central venous access related adverse 
events after trabectedin infusions in soft tissue 
sarcoma patients; experience and management 
in a nationwide multi-center study
Michiel C. Verboom1*, Jan Ouwerkerk1, Neeltje Steeghs2, Jacob Lutjeboer3, J. Martijn Kerst2,  
Winette T. A. van der Graaf4,5, Anna K. L. Reyners6, Stefan Sleijfer7 and Hans Gelderblom1
Abstract 
Background: Trabectedin has shown efficacy against soft tissue sarcomas (STS) and has manageable toxicity. Tra-
bectedin is administered through central venous access devices (VAD), such as subcutaneous ports with tunneled 
catheters, Hickman catheters and PICC lines. Venous access related adverse events are common, but have not yet 
been reported in detail.
Methods: A retrospective analysis of patient files of STS patients receiving trabectedin monotherapy between 1999 
and 2014 was performed in all five STS referral centers in the Netherlands. This survey focused on adverse events 
related to the VAD and the actions taken in response to these events.
Results: In the 127 patients included in this analysis, 102 venous access ports (VAP), 15 Hickman catheters and 10 
PICC lines were used as primary means of central venous access. The most frequently reported adverse events at the 
VAD site were erythema (30.7%), pain (28.3%), inflammation (11.8%) and thrombosis (11.0%). Actions taken towards 
these adverse events include oral antibiotics (17.3%), VAD replacement (15.0%) or a wait-and-see policy (13.4%). In 
total, 45 patients (35.4%) with a subcutaneous port developed a varying degree of inflammation along the trajectory 
of the tunneled catheter. In all but three patients, this was a sterile inflammation, which was considered a unique 
phenomenon for trabectedin. Microscopic leakage of trabectedin along the venous access device and catheter was 
considered the most plausible cause for this adverse event. Placing the catheter deeper under the skin resolved the 
issue almost completely.
Conclusion: Trabectedin infusion commonly leads to central venous access related adverse events. Sterile inflamma-
tion along the catheter trajectory is one of the most common adverse events and can be prevented by placing the 
catheter deeper under the skin.
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Background
Cytostatic drugs infused directly into peripheral veins 
can have very damaging effects on these blood vessels. 
To ensure safe and durable administration of such agents, 
several methods have been developed in the past, like 
the arteriovenous shunt, which is no longer used for the 
infusion of chemotherapy [1]. In 1982, a central venous 
access device was introduced, that used a subcutaneous 
reservoir and a tunneled catheter to provide access to the 
superior vena cava [2]. This type of central venous cath-
eters (CVC) allows for easy access to a patient’s circula-
tion, incur minimal restriction in normal activities and 
usually at a low risk of complications [3]. Next to VAPs, 
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other methods have also been introduced, such as the 
Hickman catheter and peripherally inserted CVC (PICC) 
lines [4, 5]. However, all devices constitute some risk of 
venous access related adverse events (VARAE).
As anticancer drug, trabectedin stands out as a drug 
with a unique mechanism of action, having effect both at 
the level of tumor DNA and on the tumor microenviron-
ment [6]. It is one of the few drugs active in STS [7]. The 
drug has a manageable toxicity profile, but life-threaten-
ing toxicity due to uncommon adverse events has been 
reported [8]. Thus far several papers have mentioned 
VARAE, including reports on trabectedin extravasation 
and associated thrombi on the line tip, but no papers 
focusing on VARAE in detail have been published [9–12]. 
This article aims to systematically study VARAE observed 
in 127 consecutive sarcoma patients treated with trabect-
edin and to evaluate the measures taken to handle these 
problems.
Methods
A retrospective analysis of VARAE in all patients treated 
with trabectedin was performed in all five participating 
Dutch sarcoma referral centers: the Leiden University 
Medical Center (LUMC), the Netherlands Cancer Insti-
tute Antoni van Leeuwenhoek (NKI-AvL), the Erasmus 
MC Cancer Institute (EMC), the Radboud University 
Medical Center (RUMC) and the University Medical 
Center Groningen (UMCG). Patients were eligible when 
treated with trabectedin monotherapy for advanced STS. 
Data on patient characteristics were reported as well as 
the type of venous access device, its placement, adverse 
events related to its usage and the interventions to coun-
ter these events. Adverse events related to the VAD 
placement were ignored, as these have no direct relation 
with trabectedin infusions. Hence, all events described 
occurred after at least one cycle of trabectedin had been 
given.
To test for a difference in the number of cycles per 
VAD, a Kruskal–Wallis non-parametric test was used. To 
assess differences between VARAE per VAD cross tables 
and the Chi square were computed. All statistical analy-
ses were performed using SPSS version 20.
Results
Patients
In total, 127 advanced STS patients were treated with 
single agent trabectedin between November 1999 and 
November 2014. Almost all patients were treated as part 
of an observational phase IV study or of the TRUSTS trial 
[13, 14]. Due to the inclusion criteria of these studies, tra-
bectedin was given either as first line (15.0%), second line 
(59.1%), third line (16.5%), fourth line (7.1%) or as a fur-
ther line of treatment (2.4%). The trabectedin treatment 
regimen was given at a dosage of 1.5 mg/m2 as 24 h infu-
sion every three weeks in 89.8% of patients, the remain-
ing patients received a lower dose (1.1–1.3 mg/m2) and/
or a 3 h infusion. The most prevalent types of STS histol-
ogy were leiomyosarcoma (40.9%), liposarcoma (26.0%) 
and synovial sarcoma (12.6%), as shown in Table 1.
VADs inserted
The VAP was used in 102 (80.3%) patients, of which 87 
were identified as a Smith Medical Port-a-Cath®. Hick-
man catheters and PICC lines were inserted in 15 (11.8%) 
and 10 (7.9%) of patients, respectively. A total of 540 
cycles of trabectedin were given with a median number 
of 4 cycles for the entire patient group. The number of 
cycles given did not differ significantly per VAD (data not 
shown).
Each hospital had a clear preference for a particular 
type of VAD that was initially inserted; in the LUMC 
VAPs (100% of patients), in the NKI-AvL VAPs (95%), in 
the EMC the Hickman catheter (100%), in the RUMC a 
PICC line (66.7%) and in the UMCG VAPs (100%). VADs 
were inserted by a dedicated team of health care workers 
Table 1 Patient characteristics
N (%)
Sex
 Female 66 (52.0)
 Male 61 (48.0)
Age
 Median (years) 54.3
 Range (years) 25.6–79.5
WHO performance score
 0 52 (40.9)
 1 66 (52.0)
 2 9 (7.1)
Histology
 Leiomyosarcoma 52 (40.9)
 Liposarcoma 33 (26.0)
 Synovial sarcoma 16 (12.6)
 Various others 26 (20.5)
Best response
 Partial response 8 (6.3)
 Stable disease 64 (50.4)
 Progressive disease 45 (35.4)
 Not evaluable 10 (7.9)
Hospital
 LUMC 48 (37.8)
 NKI-AvL 40 (31.5)
 EMC 15 (11.8)
 RUMC 12 (9.4)
 UMCG 12 (9.4)
Page 3 of 6Verboom et al. Clin Sarcoma Res  (2017) 7:2 
to ensure low incidence of complications related to the 
VAD placement.
Of all patients, only three patients with a Hickman 
catheter requested their VAD to be replaced by another 
type of VAD. Two of these patients preferred a VAP, but 
did not have a VARAE at the time of replacement. In 
another patient, the catheter was chronically obstructed 
due to a thrombus at the catheter tip, which required 
catheter flushing by a radiologist, despite adequate 
antithrombotic treatment.
Sterile inflammation along the catheter trajectory
Out of the 127 patients, 45 patients (35.4%) with a VAP 
developed a varying degree of inflammation along the 
catheter trajectory, which could include erythema, pain 
or swelling, as shown in Fig.  1. In between cycles these 
symptoms waned, but a few days after the following 
infusion a flare up was often noted. Fever was neither 
reported by patients, nor observed during physical exam-
ination at admission or at the outpatient clinic. The skin 
surrounding the port’s reservoir was not affected and the 
VAD could be used for infusions normally. Bacterial cul-
tures could not identify an etiological micro-organism for 
these symptoms in all, but three patients.
In the first instances these symptoms were deemed a 
result of cellulitis and oral antibiotics were prescribed 
(flucloxacillin 500  mg four times daily). However, the 
symptoms abated only mildly and the erythema remained 
unchanged for weeks and existed even after the discon-
tinuation of trabectedin therapy. Extra intravenous infu-
sion of normal saline fluids during trabectedin infusion 
appeared to ease the symptoms, especially the pain.
In a single patient with port VAD, the inflammation 
became rampant and in the course of several weeks it 
led to severe skin erosion along the catheter trajectory, 
as shown in Fig.  2. At progression of the inflammatory 
aspect of the skin, the patient was treated with oral anti-
biotics. Due to the skin destruction, a local secondary 
cellulitis developed. Despite this, the patient did not feel 
ill. As the patient did not show symptoms of acute infec-
tion, it was decided to continue trabectedin treatment. 
After trabectedin was stopped due to progressive disease, 
the VAP remained in place and was used for dacarbazine 
cycles without VARAE.
Remarkably, this complication appeared only in 
patients from one hospital and only after receiving sev-
eral trabectedin cycles, and did not occur with any other 
type of cytostatic agent. As the same brand and type of 
VAD was used in another hospital without this compli-
cation, the dedicated teams compared their respective 
methods of VAD insertion. The only apparent difference 
found, was in the depth of the subcutaneous insertion 
for tunneling the catheter. Catheter insertion can be per-
formed more or less deeper under the skin and the lat-
ter method was associated with the sterile inflammation 
along the catheter trajectory. Upon changing the local 
protocol to deepen the tunneling of the catheter, no fur-
ther events of sterile inflammation of the catheter trajec-
tory were observed.
Adverse events related to VAD
All types of VADs used had VARAE, as shown in Table 2. 
For the whole patient cohort, the most common adverse 
events were erythema (30.7%) and pain (28.3%) at the 
VAD site or along the catheter trajectory. In 11.8% of 
Fig. 1 Typical sterile inflammation along the venous access port 
catheter trajectory
Fig. 2 Skin erosion along venous access port catheter trajectory due 
to severe sterile inflammation
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patients these symptoms were diagnosed as an inflam-
mation and/or infection, where inflammation consisted 
of swelling, painfulness and erythema. Blood cultures did 
not grow pathogenic micro-organisms. In some of these 
patients the ‘infection’ diagnosis could retrospectively be 
reclassified as the previously described sterile inflamma-
tion with near certainty. Several patients (11.0%) had a 
thrombus at the catheter tip at one or several instances. 
Often, these thrombi could be flushed with urokinase 
solution before proceeding to administer the trabect-
edin infusion without further complications. However, 
catheter thrombosis could also lead to VAD impairment. 
Remarkably, all of these patients were treated in the same 
hospital, which was also the hospital were VAPs were 
inserted with tunneled catheters deep in the epidermis. 
Thrombosis at the catheter tip and the sterile inflamma-
tion were not significantly associated (data not shown). 
The skin erosion and extravasation of trabectedin were 
seldom seen. Dislocation or pinch-off was not seen in 
any patient. Due to the small number of patients with a 
Hickman catheter or PICC line, no statistical differences 
in the incidence of VARAE could be detected. Only a sin-
gle patient (0.8%), who had a Hickman catheter, had an 
extravasation.
Interventions for VARAE
Oral antibiotics were given in 17.3% of patients, most 
often flucloxacillin, as shown in Table  3. Some patients 
received a prescription for oral antibiotics to be taken 
in case VAD related symptoms worsened. Although this 
was not sufficient to stop the erythema along the catheter 
trajectory, it may have helped against a secondary infec-
tion. In 5 patients (3.9%) VAD an infection necessitated 
IV antibiotics (2 patients with a VAP, 3 patients with 
a PICC line). Due to the severity of symptoms or VAD 
impairment VAD replacement was needed in 15.0% of 
patients. Patients with a VAP usually had the same type 
of VAP inserted at the contralateral side, patients with 
a Hickman catheter or PICC line most often received a 
VAP. As the problem of the sterile inflammation and 
other VARAE were better understood and recognized, 
in due course a wait-and-see policy was applied in a con-
siderable number of patients (13.4%). Despite frequent 
complaints of pain at the VAD site, analgesics were only 
needed in a minority of these patients.
Discussion
Trabectedin is one of the proven active drugs in the 
treatment of soft tissue sarcoma and is given through a 
central venous catheter to avoid peripheral vein dam-
age. As treatment continues until progressive disease or 
unacceptable toxicity, is it important to evaluate cath-
eter related complications. The sterile inflammation 
along the catheter trajectory found in this study was an 
unexpected VARAE and was initially poorly understood. 
Erythema or pain is usually taken as a sign of skin infec-
tion and treated as such. However, there were no other 
signs of infection such as positive cultures, and the sever-
ity of the skin complications appeared to be related to 
the administration of trabectedin. In addition, the ery-
thema was most prominent along the catheter trajectory, 
which made a porous catheter likely to be the cause. A 
direct effect of trabectedin on the tissue surrounding the 
catheter could cause the inflammation, but this catheter 
porosity implies that only a small quantity of trabectedin 
permeates. This small quantity leads to fewer symptoms 
compared to a full trabectedin extravasation, as has been 
reported in literature [11].
Table 2 Adverse events at VAD site/trajectory per venous access device
a Summary of all types of adverse events per venous access device
N (%) Inflammation Erythema Pain Infection Thrombosis Impairment Erosion Extravasation All AEa
Venous access port (102) 35 (34.3) 30 (29.4) 28 (27.5) 9 (8.8) 11 (10.8) 5 (4.9) 1 (1.0) 0 (0.0) 44 (43.1)
Hickman line (15) 5 (33.3) 4 (26.7) 4 (26.7) 3 (20.0) 1 (6.7) 3 (20.0) 0 (0.0) 1 (6.7) 7 (46.7)
PICC line (10) 5 (50.0) 5 (50.0) 4 (40.0) 3 (30.0) 2 (20.0) 1 (10.0) 0 (0.0) 0 (0.0) 5 (50.0)
Total 45 (35.4) 39 (30.7) 36 (28.3) 15 (11.8) 14 (11.0) 9 (7.1) 1 (0.8) 1 (0.8) 56 (44.1)
Table 3 Interventions for VAD related adverse events per venous access device
N (%) Antibiotics (oral) VAD replaced Wait-and-see Analgesics Urokinase (IV) Antibiotics (IV)
Venous access port (102) 19 (18.6) 10 (9.8) 13 (12.7) 8 (7.8) 8 (7.8) 2 (2.0)
Hickman line (15) 1 (6.7) 6 (40.0) 3 (20.0) 2 (13.3) 1 (6.7) 0 (0.0)
PICC line (10) 2 (20.0) 3 (30.0) 1 (10.0) 0 (0.0) 0 (0.0) 3 (30.0)
Total 22 (17.3) 19 (15.0) 17 (13.4) 10 (7.9%) 9 (7.1) 5 (3.9)
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To investigate the hypothesis of catheter porosity, the 
manufacturer of trabectedin, PharmaMar, offered to test 
a used catheter. A VAP was available that was previously 
used in a patient who had received several cycles of tra-
bectedin with symptoms of sterile inflammation along-
side the catheter trajectory and from whom the VAP was 
removed because of disease progression. The objective of 
the test was to determine if trabectedin permeates from 
the internal surface to the outside of the catheter dur-
ing a 24  h infusion. High-performance liquid chroma-
tography with diode array detection (HPLC–DAD) and 
multi-syringe flow injection system (MS-FIA) methods 
were used for detection of trabectedin in the dextrose 5% 
solution the VAP was submerged in. Neither test could 
detect trabectedin in samples taken from the dextrose 5% 
solution, which ruled out gross catheter porosity (Phar-
maMar communication). In our view, however, this could 
not rule out sub lower-limit of quantification leakage.
Non-infectious inflammation of the VAD site of vari-
ous severity was also reported by Hoicyk et  al. in addi-
tion of thrombi at the catheter tip. It was hypothesized 
that increased resistance due to small thrombi may be 
associated with drug backspill [12]. In the current study, 
neither an association of sterile inflammation and throm-
bosis was found, nor was reduced flow through the cath-
eter observed. Catheter thrombosis occurred in several 
patients, which was treated by flushing the catheter with 
an urokinase solution. Thrombosis prophylaxis was not 
initiated at the start of trabectedin therapy in any of the 
participating centres.
In the patient cohort only a small number of patients 
had PICC lines. A larger retrospective series of STS and 
ovarian cancer patients was reported by Martella and col-
leagues. Out of 45 patients with a PICC line receiving tra-
bectedin a device dislocation was reported in two patients 
and an infection in another two. PICC line malfunction or 
VARAE requiring VAD removal did not occur [10]. This 
implies that PICC lines may have lower incidence of asso-
ciated toxicity than our current cohort suggests. How-
ever, the number of VARAE in patients using a PORT was 
also lower. Due to the retrospective nature of this patient 
series, relative underreporting compared to our study may 
have occurred, as almost all patient in this cohort where 
treated as part of a clinical trial.
The usage of a disposable elastomeric pump to admin-
ister a 24-h trabectedin infusion has been described [9]. 
Patients could choose for a regular VAP or a Baxter LV10 
Pump which allowed patients to spend the night at home. 
Out of 28 patients 21 chose the ambulatory pump. This 
method was considered feasible and safe. However, most 
patients will receive trabectedin trough conventional 
VAPs reported on in this paper, and no data is available 
comparing these different techniques.
Compared to published safety data, the rate of 
observed trabectedin extravasation of 0.8% in our series 
was similar to 0.5% reported in large pooled analysis of 
1132 patients who received single agent trabectedin [8].
Conclusions
Despite the use of central venous access devices, tra-
bectedin can cause local sterile inflammation along the 
catheter trajectory, in particular in venous access ports. 
Positioning the port’s catheter deeper in the subcu-
tis appears to be the most efficient way to prevent this 
complication.
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